Search results
CKPT Investors Have Opportunity to Lead Checkpoint Therapeutics, Inc. Securities Fraud Lawsuit
WTNH-TV New Haven· 1 day agoLaw Offices of Howard G. Smith announces that investors with substantial losses have opportunity to...
AKRO Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges Akero Therapeutics, Inc. Investors...
WJET - WFXP Erie· 6 days ago("Akero") (NASDAQ: AKRO). As a result of Akero's materially misleading statements and omissions to...
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit
KTLA-TV Los Angeles· 4 days agoThe Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Akero Therapeutics
FDA Approves Pivya, a New Treatment for UTIs in Women
Health.com· 5 days agoCompared to complicated UTIs, uncomplicated ones are less severe and more prevalent, affecting more...
Earnings call: Autolus Therapeutics Reports Progress and Financials for Q1 2024 By Investing.com
Investing.com· 7 days agoIn a recent earnings call, Autolus Therapeutics (NASDAQ:AUTL), a biopharmaceutical company...
XPeng Posts Strong Results, Joins Larimar Therapeutics, Transcat And Other Big Stocks Moving Higher...
Benzinga· 4 days agoHere are some other big stocks recording gains in today's session. Waldencast plc WALD shares...
Larimar Therapeutics Shares Up 22%, FDA Lifts Hold for Nervous System Disorder Treatment
Morningstar· 5 days agoShares of Larimar Therapeutics were trading higher in after-hours action Monday, following news the U.S. Food and Drug Administration has lifted a partial clinical hold on ...
FDA Grants Withdrawal of Infigratinib for Cholangiocarcinoma
Medscape· 5 days agoThe US Food and Drug Administration (FDA) has announced the withdrawal of its 2021 accelerated approval of infigratinib (Truseltiq) for patients with a certain type of previously ...
ADDF invests $5 million in Coya Therapeutics for FTD treatment By Investing.com
Investing.com· 5 days agoCoya Therapeutics, Inc. (NASDAQ:COYA), a biotech firm focusing on regulatory T cell therapies, has...
Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement - Kazia ...
Benzinga· 2 days agoKazia Therapeutics Limited KZIA (Kazia or the company) received a letter on May 22, 2024 from Nasdaq notifying the Company that, while the Company has not regained compliance ...